DECREASED SEXUAL FUNCTION IN PATIENTS WITH OVERACTIVE BLADDER: INTERIM RESULTS FROM THE MATRIX STUDY

P.K. Sand, R. Goldberg, V. Lucente

Evanston Continence Center, Evanston, IL; Northwestern University, Feinberg School of Medicine, Chicago, IL

OBJECTIVE: This analysis was conducted to determine the impact of overactive bladder (OAB) on sexual function by examining baseline data from an interim analysis of the MATRIX (Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin) study.

MATERIALS AND METHODS: The MATRIX study is an open-label, prospective, randomized trial that will enroll 2500 adult patients who have been diagnosed with OAB. Data obtained for this analysis are taken from patient responses to validated questionnaires (the King’s Health Questionnaire and the Beck Depression Inventory II) and are used to determine the impact of OAB on sexual function. These findings are compared with the duration of patients’ OAB symptoms and treatment history.

RESULTS: Among the 676 patients enrolled to date, the mean age is 62.4 y (±14.4 y), 580 (86%) of the patients are female, and 573 (85%) are Caucasian. Responses to the King’s Health Questionnaire reveal that 161 (23.8%) of the participants report that OAB impacts their sex life, with 152 (22.5%) experiencing urinary incontinence during intercourse. Beck Depression Inventory II responses indicate less interest, much less interest, or complete loss of  interest in sex in 311 (46%) of all study participants. Complete loss of interest in sex is reported by 54 (20%) of the 271 patients experiencing OAB symptoms for 4 or more years compared with 11 (14.6%) of the 75 patients who have had symptoms for 1 year or less. Similarly, 75 (21%) of the 362 patients with a history of previous treatment for their OAB symptoms report having lost all interest in sex compared with 34 (14%) of the 243 patients who have never been previously treated for their OAB symptoms.

CONCLUSIONS: Overactive bladder in adults appears to negatively affect sexual function. Additionally, the severity of sexual dysfunction may be related to symptom duration and to treatment history.

Disclosure – Consultant: R. Goldberg, Watson; V. Lucente, Watson; Speakers Bureau: P.K. Sand, Alza/Ortho-McNeil, Watson, American Medical Systems; Advisory Board: P.K. Sand, Alza/Ortho-McNeil, Watson, American Medical Systems, Indevus, Yamanouchi, Roche, Pfizer, Bioform, Lilly, Boeringer-Ingelheim, Mentor, Novasys; Grant/Research: P.K. Sand, Alza/Ortho-McNeil, Watson, American Medical Systems, Indevus, Yamanouchi, Roche, Pfizer, Bioform, Lilly, Boeringer-Ingelheim, Mentor, Novasys.